• Paper cites IceCure's ICE3 interim clinical study results as evidence of safety and efficacy of cryoablation in early-stage breast cancer

CAESAREA, Israel, Oct. 25, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense^® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that a scientific paper titled "Cryoablation Therapy for Early-Stage Breast Cancer: Evidence and Rationale" was recently published in the Journal of Breast Imaging.

Highlights of the paper, which cited the efficacy and safety of interim results from IceCure's ICE3 study of ProSense® in early-stage breast cancer, included:

• Technological advances are propelling a paradigm shift toward less aggressive and less invasive treatment for early-stage breast cancer
• Patients most likely to benefit from a less aggressive approach with local therapy are those with small, low-risk tumors
• Cryoablation of breast cancer is an emerging nonsurgical treatment alternative to breast conserving surgery
• Cryoablation's advantages as compared to surgery include faster recovery, improved cosmetics, local anesthesia
• Liquid nitrogen based cryoablation system has the advantage of smaller footprint …relatively in expensive and readily available
• The best candidates for cryoablation are those with low grade, hormone receptor positive, and ≤1.5 cm in size tumors
• Further studies are needed to determine longer-term outcomes, including disease-free and overall survival after cryoablation therapy

The paper's co-authors include ProSense^® users, Robert C. Ward, MD, Assistant Professor of Diagnostic Imaging at the Warren Alpert Medical School of Brown University, Program Director for the Breast Imaging Fellowship, Associate Chief of Diagnostic Imaging at Women & Infants Hospital, Providence, Rhode Island; and Alexander B. Sevrukov, MD, Sidney Kimmel College of Medicine, Thomas Jefferson University, Department of Radiology, Division of Breast Imaging, Philadelphia, Pennsylvania.

Dr. Ward, a ProSense^® user who specializes in women's imaging and breast tumor cryoablation, commented, "Combining breast imaging with minimally invasive procedures such as cryoablation with ProSense® is changing the paradigm of treatment for breast cancer. We've seen excellent results in early-stage patients and the growing body of evidence published by practitioners around the world validates the results we are seeing first hand." 

"We are grateful to the doctors who took the time and care to assess the literature, write, and publish this independent, non-sponsored scientific paper. Our interim ICE3 results were a key part of the data used in this paper and we look forward to announcing the complete topline data in the first quarter of 2024," stated IceCure's CEO, Eyal Shamir. "Papers like this, combined with several independent studies of ProSense® cryoablation recently published, help to inform doctors and patients about how cryoablation can significantly improve patient outcomes and avoid aggressive treatment when it's not necessary," 

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China. 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal and Israeli securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statement in this press release when it discusses that cyroablation is changing the paradigm of treatment for breast cancer, that the Company looks forward to announcing the complete topline data in the first quarter of 2024, and how cryoablation can significantly improve patient outcomes and avoid aggressive treatment when it is not necessary.

Historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of IceCure could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on March 29, 2023, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR Contact:

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462